Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 65Unknown 9Terminated 9Recruiting 7Not yet recruiting 5Withdrawn 3Active not recruiting 3Enrolling by invitation 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 846Carcinoma, Non-Small-Cell Lung 553Neoplasms 516Prostatic Neoplasms 503Lung Neoplasms 312Colorectal Neoplasms 304Multiple Myeloma 295Neoplasm Metastasis 255Melanoma 244Ovarian Neoplasms 215Leukemia, Myeloid, Acute 212Pancreatic Neoplasms 203Squamous Cell Carcinoma of Head and Neck 171Carcinoma, Renal Cell 166Stomach Neoplasms 160Recurrence 159Lymphoma 159Carcinoma, Hepatocellular 159Glioblastoma 151Brain Neoplasms 151Lymphoma, Non-Hodgkin 143Uterine Cervical Neoplasms 142Head and Neck Neoplasms 141Urinary Bladder Neoplasms 137Leukemia, Lymphocytic, Chronic, B-Cell 137Triple Negative Breast Neoplasms 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 117Colonic Neoplasms 117Lymphoma, Follicular 114

Interventions

fezolinetant 1bazedoxifene 1Tamoxifen 1Estrogens, Conjugated (USP) 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Hot Flashes × Clear all
NCT05587296 2026-05-06

OASIS-4

Bayer

Phase 3 Active not recruiting
474 enrolled 14 charts

Hot Flashes

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Astellas Pharma Inc

Phase 3 Active not recruiting
984 enrolled

Hot Flashes

NCT04821141 2025-10-29

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

University of Kansas Medical Center

Phase 2 Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Hot Flashes, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡